SCHEMBL26170243

SCHEMBL26170243

O=C(OCc1ccccc1)c1ncc(-c2cccc(Cl)c2)cc1O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 7/20 0.58
EGLN3 Q9H6Z9 4/20 0.58
VEGFA P15692 3/20 0.58
FLT1 P17948 3/20 0.58
TET3 O43151 1/20 0.58
BBOX1 O75936 1/20 0.58
ASPH Q12797 1/20 0.58
TET2 Q6N021 1/20 0.58
KDM8 Q8N371 1/20 0.58
OGFOD1 Q8N543 1/20 0.58
TET1 Q8NFU7 1/20 0.58
HIF1AN Q9NWT6 1/20 0.58
ALOX5 P09917 1/20 0.44
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
POLB P06746 1/20 0.43
TDP1 Q9NUW8 2/20 0.43
MAOA P21397 1/20 0.43
MAOB P27338 1/20 0.43
MAPT P10636 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30748269 0.80 EGLN1 (0.69) EGLN1EGLN3VEGFAFLT1TET3
SCHEMBL30432292 0.80 EGLN1 (0.69) EGLN1EGLN3VEGFAFLT1TET3
SCHEMBL25241500 0.80 EGLN1 (0.69) EGLN1EGLN3VEGFAFLT1TET3
SCHEMBL30514566 0.80 EGLN1 (0.68) EGLN1EGLN3VEGFAFLT1TET3
SCHEMBL4370919 0.80 EGLN1 (0.68) EGLN1EGLN3VEGFAFLT1TET3
SCHEMBL23501775 0.77 MAP4K4 (0.49) EGLN1EGLN3VEGFAFLT1TET3
SCHEMBL3031405 0.76 EGLN1 (0.63) EGLN1EGLN3VEGFAFLT1TET3
SCHEMBL19393710 0.76 EGLN1 (0.63) EGLN1EGLN3VEGFAFLT1TET3
SCHEMBL30346108 0.76 EGLN1 (0.63) EGLN1EGLN3VEGFAFLT1TET3
SCHEMBL3031409 0.76 EGLN1 (0.63) EGLN1EGLN3VEGFAFLT1TET3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159462-A1 METHOD FOR PRODUCING NITROGEN-CONTAINING HETEROARYLCARBOXAMIDE ACETIC ACID DERIVATIVE KREOS CAPITAL VII (UK) LIMITED (GB) 2023-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159462-A1 METHOD FOR PRODUCING NITROGEN-CONTAINING HETEROARYLCARBOXAMIDE ACETIC ACID DERIVATIVE DIMT1, DLAT, COASY EGLN1 1247/4885EGLN3 1117/4885VEGFA 747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.